572 research outputs found

    Chinese and Japanese Literati Painting: Analysis and Contrasts in Japanese Bunjinga Paintings

    Get PDF
    Senior Project submitted to The Division of Arts of Bard College

    Bendamustine-induced immune hemolytic anemia in a chronic lymphocytic leukemia patient: A case report and review of the literature

    Get PDF
    Bendamustine is an alkylating agent approved for the treatment of chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma. There are scant reports on bendamustine-induced immune hemolytic anemia occurring mainly in CLL patients. We report a case of immune hemolytic anemia that developed after exposure to bendamustine in a 70-year-old female with CLL who was previously exposed to fludarabine. Previous exposure to fludarabine is a common finding in the majority of reported cases of bendamustine drug-induced immune hemolytic anemia (DIIHA), including our case. Bendamustine should be suspected as the cause of any hemolytic anemia that develops while on this drug, especially in CLL patients treated previously with fludarabine

    Detection of analytes using metal nanoparticle probes and dynamic light scattering (US)

    Get PDF
    Disclosed herein are systems and methods for detecting Chemical Species, Biomolecules and Biotargets (Analytes) using receptor functionalized metal nanoparticles and Dynamic Light Scattering

    Clinical Challenges of Primary Diffuse Large B-Cell Lymphoma of the Dura: Case Report and Literature Review

    Get PDF
    Primary dural lymphoma is a rare disease with more indolent clinical behavior compared to primary central nervous system lymphoma. The majority of the reported cases were indolent marginal zone lymphoma subtype with more predilections to the spine. Herein, we are presenting a case of intracranial, diffuse large B-cell lymphoma of the dura that was diagnosed and treated at our institution. We are presenting the challenges in the treatment based on a review of the literature

    Causes of death and conditional survival estimates of long-term lung cancer survivors.

    Get PDF
    INTRODUCTION: Lung cancer ranks the leading cause of cancer-related death worldwide. This retrospective cohort study was designed to determine time-dependent death hazards of diverse causes and conditional survival of lung cancer. METHODS: We collected 816,436 lung cancer cases during 2000-2015 in the SEER database, after exclusion, 612,100 cases were enrolled for data analyses. Cancer-specific survival, overall survival and dynamic death hazard were assessed in this study. Additionally, based on the FDA approval time of Nivolumab in 2015, we evaluated the effect of immunotherapy on metastatic patients\u27 survival by comparing cases in 2016-2018 (immunotherapy era, n=7135) and those in 2013-2016 (non-immunotherapy era, n=42061). RESULTS: Of the 612,100 patients, 285,705 were women, the mean (SD) age was 68.3 (11.0) years old. 252,558 patients were characterized as lung adenocarcinoma, 133,302 cases were lung squamous cell carcinoma, and only 78,700 cases were small cell lung carcinomas. TNM stage was I in 140,518 cases, II in 38,225 cases, III in 159,095 cases, and IV in 274,262 patients. 164,394 cases underwent surgical intervention. The 5-y overall survival and cancer-specific survival were 54.2% and 73.8%, respectively. The 5-y conditional survival rate of cancer-specific survival is improved in a time-dependent pattern, while conditional overall survival tends to be steady after 5-y follow-up. Except from age, hazard disparities of other risk factors (such as stage and surgery) diminished over time according to the conditional survival curves. After 8 years since diagnosis, mortality hazard from other causes became higher than that from lung cancer. This critical time point was earlier in elder patients while was postponed in patients with advanced stages. Moreover, both cancer-specific survival and overall survival of metastatic patients in immunotherapy era were significantly better than those in non-immunotherapy era (P CONCLUSIONS: Our findings expand on previous studies by demonstrating that non-lung-cancer related death risk becomes more and more predominant over the course of follow-up, and we establish a personalized web-based calculator to determine this critical time point for long-term survivors. We also confirmed the survival benefit of advanced lung cancer patients in immunotherapy era

    [1,1′-Bis(diphenyl­phosphino)cobalto­cenium-κ2 P,P′]dichloridoplatinum(II) hexa­fluorido­phosphate

    Get PDF
    The title bimetallic compound, [PtCl2{Co(C17H14P)2}]PF6, was obtained by reaction of 1,1′-bis­(diphenyl­phosphino)cobalto­cenium hexa­fluorido­phosphate with bis­(acetonitrile)di­chloridoplatinum. The PtII ion is four-coordinated in a slightly distorted square-planar environment by two P atoms of the 1,1′-bis­(diphenyl­phosphino)cobaltocenium moiety and two Cl atoms. In the crystal structure, mol­ecules are linked by weak C—H⋯F and C—H⋯Cl hydrogen bonds
    corecore